Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis c virus genotype 1

Andrea Calcagno; Lucio Boglione; Francesco Giuseppe De Rosa; Giovanni Di Perri; Stefano Bonora

doi:10.1093/cid/cit087

Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis c virus genotype 1

Andrea Calcagno, Lucio Boglione, Francesco Giuseppe De Rosa, Giovanni Di Perri, Stefano Bonora

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1677-1678
Number of pages	2
Journal	Clinical Infectious Diseases
Volume	56
Issue number	11
DOIs	https://doi.org/10.1093/cid/cit087
Publication status	Published - 1 Jun 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/cit087

Cite this

@article{f1355b62d1c34b699454deb8a41c8514,

title = "Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis c virus genotype 1",

author = "Andrea Calcagno and Lucio Boglione and {De Rosa}, {Francesco Giuseppe} and {Di Perri}, Giovanni and Stefano Bonora",

year = "2013",

month = jun,

day = "1",

doi = "10.1093/cid/cit087",

language = "English",

volume = "56",

pages = "1677--1678",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis c virus genotype 1

AU - Calcagno, Andrea

AU - Boglione, Lucio

AU - De Rosa, Francesco Giuseppe

AU - Di Perri, Giovanni

AU - Bonora, Stefano

PY - 2013/6/1

Y1 - 2013/6/1

UR - http://www.scopus.com/inward/record.url?scp=84877247924&partnerID=8YFLogxK

U2 - 10.1093/cid/cit087

DO - 10.1093/cid/cit087

M3 - Letter

C2 - 23418276

AN - SCOPUS:84877247924

SN - 1058-4838

VL - 56

SP - 1677

EP - 1678

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 11

ER -

Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis c virus genotype 1

UN SDGs

Access to Document

Other files and links

Cite this